Drug Combination Details
| General Information of the Combination (ID: C23832) | |||||
|---|---|---|---|---|---|
| Name | Exemestane | + | Triptorelin + Cisplatin | ||
| Click to Show/Hide the Each NP or Drug Information of This Combination | |||||
| Name | Exemestane NP Info | Drug Info | |||
| Structure |
|
|
|||
| Name | Drug Info | ||||
| Structure |
|
|
|||
| Disease |
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
|
| In-vivo Model | Ascites OT (5*106) cells were intraperitoneally transplanted in female Wistar rats. | |||||
| Experimental
Result(s) |
Triptorelin and exemestane increase antitumor activity of cisplatin in respect to the transplantable malignant ascites OT and significantly increase survival of animals, especially when triptorelin and cisplatin are used in combination. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | The antitumor efficacy of cisplatin in combination with triptorelin and exemestane therapy for an ovarian cancer ascites model in Wistar rats. Exp Oncol. 2015 Mar;37(1):30-5. | |||
